EcoDrugPlus

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSLACG00000002601
Gene Symbol: FNTA
4 Cross references
221 Possible Orthologues:

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSLACG00000016800
Gene Symbol: FNTB
4 Cross references
210 Possible Orthologues:

Fibroblast Growth Factor 2

Ensembl ID : ENSLACG00000016890
Gene Symbol: FGF2
4 Cross references
122 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSLACG00000013549
Gene Symbol: FGFR1
4 Cross references
293 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSLACG00000006604
Gene Symbol: FGFR2
4 Cross references
219 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSLACG00000000568
Gene Symbol: FGFR3
4 Cross references
196 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSLACG00000017415
Gene Symbol: FLT1
3 Cross references
198 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSLACG00000012631
Gene Symbol: FLT4
4 Cross references
195 Possible Orthologues:

Folate Receptor

Ensembl ID : ENSLACG00000000045
Gene Symbol: FOLR
1 Cross references
436 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSLACG00000000312
Gene Symbol: LOC102358678
3 Cross references
450 Possible Orthologues:

Free Fatty Acid Receptor 3-Like

Ensembl ID : ENSLACG00000001802
Gene Symbol: LOC102367457
3 Cross references
450 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSLACG00000000219
Gene Symbol: FRK
4 Cross references
216 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).